Literature DB >> 17425653

Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy.

C K Wong1, A W Y Ho, P C Y Tong, C Y Yeung, A P S Kong, S W M Lun, J C N Chan, C W K Lam.   

Abstract

Cytokine-induced inflammation is involved in the pathogenesis of type 2 diabetes mellitus (DM). We investigated plasma concentrations and ex vivo production of cytokines and chemokines, and intracellular signalling molecules, mitogen-activated protein kinases (MAPK) in T helper (Th) cells and monocytes in 94 type 2 diabetic patients with or without nephropathy and 20 healthy controls. Plasma concentrations of inflammatory cytokines tumour necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-18 and chemokine CCL2 in patients with diabetic nephropathy (DN) were significantly higher than control subjects, while IL-10, CXCL8, CXCL9, CXCL10 and adiponectin concentrations of DN were significantly higher than patients without diabetic nephropathy (NDN) and control subjects (all P < 0.05). Plasma concentrations of TNF-alpha, IL-6, IL-10, IL-18, CCL2, CXCL8, CXCL9, CXCL10 and adiponectin exhibited significant positive correlation with urine albumin : creatinine ratio in DN patients. The percentage increases of ex vivo production of IL-6, CXCL8, CXCL10, CCL2 and CCL5 upon TNF-alpha activation were significantly higher in both NDN and DN patients than controls (all P < 0.05). The percentage increases in IL-18-induced phosphorylation of extracellular signal-regulated kinase (ERK) in Th cells of NDN and DN were significantly higher than controls (P < 0.05), while the percentage increase in TNF-alpha-induced phosphorylation of p38 MAPK in monocytes and IL-18-induced phosphorylation of p38 MAPK in Th cells and monocytes were significantly higher in NDN patients than controls. These results confirmed that the aberrant production of inflammatory cytokines and chemokines and differential activation of MAPK in different leucocytes are the underlying immunopathological mechanisms of type 2 DM patients with DN.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17425653      PMCID: PMC1942021          DOI: 10.1111/j.1365-2249.2007.03389.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

Review 1.  Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation.

Authors:  J M Kyriakis; J Avruch
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

Review 2.  ERK implication in cell cycle regulation.

Authors:  Jean-Claude Chambard; Renaud Lefloch; Jacques Pouysségur; Philippe Lenormand
Journal:  Biochim Biophys Acta       Date:  2006-11-17

3.  Significance of chemokines and activated platelets in patients with diabetes.

Authors:  S Nomura; A Shouzu; S Omoto; M Nishikawa; S Fukuhara
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

4.  Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress.

Authors:  Katherine Esposito; Francesco Nappo; Raffaele Marfella; Giovanni Giugliano; Francesco Giugliano; Myriam Ciotola; Lisa Quagliaro; Antonio Ceriello; Dario Giugliano
Journal:  Circulation       Date:  2002-10-15       Impact factor: 29.690

5.  Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.

Authors:  C Weyer; T Funahashi; S Tanaka; K Hotta; Y Matsuzawa; R E Pratley; P A Tataranni
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

6.  Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy.

Authors:  Kyouichi Tashiro; Ichiro Koyanagi; Akemi Saitoh; Ayumi Shimizu; Toshihide Shike; Chizuru Ishiguro; Michiko Koizumi; Kazuhiko Funabiki; Satoshi Horikoshi; Isao Shirato; Yasuhiko Tomino
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

Review 7.  Oxidative stress, inflammation, and diabetic vasculopathies: the role of alpha tocopherol therapy.

Authors:  I Jialal; S Devaraj; S K Venugopal
Journal:  Free Radic Res       Date:  2002-12

8.  Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue.

Authors:  Noriyuki Ouchi; Shinji Kihara; Tohru Funahashi; Tadashi Nakamura; Makoto Nishida; Masahiro Kumada; Yoshihisa Okamoto; Koji Ohashi; Hiroyuki Nagaretani; Ken Kishida; Hitoshi Nishizawa; Norikazu Maeda; Hideki Kobayashi; Hisatoyo Hiraoka; Yuji Matsuzawa
Journal:  Circulation       Date:  2003-02-11       Impact factor: 29.690

9.  Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population.

Authors:  Yukihiro Yamamoto; Hiroshi Hirose; Ikuo Saito; Motowo Tomita; Matsuo Taniyama; Koichi Matsubara; Yasunori Okazaki; Tatsuya Ishii; Kanako Nishikai; Takao Saruta
Journal:  Clin Sci (Lond)       Date:  2002-08       Impact factor: 6.124

10.  A central role for JNK in obesity and insulin resistance.

Authors:  Jiro Hirosumi; Gürol Tuncman; Lufen Chang; Cem Z Görgün; K Teoman Uysal; Kazuhisa Maeda; Michael Karin; Gökhan S Hotamisligil
Journal:  Nature       Date:  2002-11-21       Impact factor: 49.962

View more
  39 in total

1.  Aberrant expression of soluble co-stimulatory molecules and adhesion molecules in type 2 diabetic patients with nephropathy.

Authors:  C K Wong; Amy W Y Ho; Peter C Y Tong; C Y Yeung; Juliana C N Chan; Alice P S Kong; Christopher W K Lam
Journal:  J Clin Immunol       Date:  2007-11-17       Impact factor: 8.317

Review 2.  From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy.

Authors:  Ying Qian; Eva Feldman; Subramanian Pennathur; Matthias Kretzler; Frank C Brosius
Journal:  Diabetes       Date:  2008-06       Impact factor: 9.461

Review 3.  Inflammation in diabetic kidney disease.

Authors:  Patricia M García-García; María A Getino-Melián; Virginia Domínguez-Pimentel; Juan F Navarro-González
Journal:  World J Diabetes       Date:  2014-08-15

Review 4.  Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets.

Authors:  Raimund Pichler; Maryam Afkarian; Brad P Dieter; Katherine R Tuttle
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-24

5.  Cytokines profile and its correlation with endothelial damage and oxidative stress in patients with type 1 diabetes mellitus and nephropathy.

Authors:  Rodrigo M C Pestana; Caroline P Domingueti; Rita C F Duarte; Rodrigo B Fóscolo; Janice S Reis; Ana Maria S Rodrigues; Laís B Martins; Lirlândia P Sousa; Daniela P Lage; Cláudia N Ferreira; Adaliene V M Ferreira; Ana P Fernandes; Karina B Gomes
Journal:  Immunol Res       Date:  2016-08       Impact factor: 2.829

Review 6.  Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy.

Authors:  Juan F Navarro-González; Carmen Mora-Fernández; Mercedes Muros de Fuentes; Javier García-Pérez
Journal:  Nat Rev Nephrol       Date:  2011-05-03       Impact factor: 28.314

7.  Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes.

Authors:  Monika A Niewczas; Linda H Ficociello; Amanda C Johnson; William Walker; Elizabeth T Rosolowsky; Bijan Roshan; James H Warram; Andrzej S Krolewski
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 8.237

Review 8.  Diabetes and its comorbidities--where East meets West.

Authors:  Alice P S Kong; Gang Xu; Nicola Brown; Wing-Yee So; Ronald C W Ma; Juliana C N Chan
Journal:  Nat Rev Endocrinol       Date:  2013-05-28       Impact factor: 43.330

Review 9.  Significance of CXCL12 in type 2 diabetes mellitus and its associated complications.

Authors:  Mojgan Noroozi Karimabad; Gholamhossein Hassanshahi
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

10.  More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial.

Authors:  Jose S Pulido; Jose E Pulido; Clement J Michet; Richard G Vile
Journal:  Retina       Date:  2010-01       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.